GlobeNewswire: Biodel Inc. Contains the last 10 of 40 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T07:00:25ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2014/05/13/636006/10081567/en/Biodel-Reports-Second-Quarter-Fiscal-Year-2014-Financial-Results.html?f=22&fvtc=4&fvtv=14213Biodel Reports Second Quarter Fiscal Year 2014 Financial Results2014-05-13T20:00:00Z<![CDATA[Conference Call and Audio Webcast Will be Held Today, May 13th, at 5:00 p.m. ET DANBURY, Conn., May 13, 2014 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the second fiscal quarter ended March 31, 2014 and provided an update on recent corporate and drug candidate portfolio developments.]]>https://www.globenewswire.com/news-release/2014/05/07/634174/10080604/en/Biodel-to-Report-Second-Quarter-Fiscal-Year-2014-Financial-Results-on-May-13-2014.html?f=22&fvtc=4&fvtv=14213Biodel to Report Second Quarter Fiscal Year 2014 Financial Results on May 13, 20142014-05-07T20:00:00Z<![CDATA[DANBURY, Conn., May 7, 2014 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) will issue its second quarter fiscal year 2014 financial results on May 13, 2014. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.]]>https://www.globenewswire.com/news-release/2014/04/22/628698/10077759/en/Biodel-Announces-Collaboration-Agreement-With-HEC-Pharm-for-Development-of-Ultra-Rapid-Acting-Insulin-Aspart-Formulation.html?f=22&fvtc=4&fvtv=14213Biodel Announces Collaboration Agreement With HEC Pharm for Development of Ultra-Rapid-Acting Insulin Aspart Formulation2014-04-22T20:00:00Z<![CDATA[DANBURY, Conn., April 22, 2014 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced the signing of a research supply and technology development agreement with the HEC Pharm subsidiary Yichang Chang Jiang Pharmaceutical Co., Ltd for ultra-rapid-acting insulin aspart. Under the agreement, HEC will supply insulin aspart, the active pharmaceutical ingredient (API) in Novolog]]>https://www.globenewswire.com/news-release/2014/03/05/615985/10071362/en/Biodel-Announces-Commercial-Manufacturing-Agreement-With-Emergent-BioSolutions-for-Glucagon-Rescue-Product.html?f=22&fvtc=4&fvtv=14213Biodel Announces Commercial Manufacturing Agreement With Emergent BioSolutions for Glucagon Rescue Product2014-03-05T21:00:00Z<![CDATA[DANBURY, Conn., March 5, 2014 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced another development in its Glucagon Emergency Management (GEM) development program with the signing of a long-term manufacturing agreement with Cangene bioPharma Inc. doing business as Emergent BioSolutions ("Emergent"). Under the agreement, Emergent will fill and finish commercial quantities of the GEM device. Financial terms of the agreement have not been disclosed.]]>https://www.globenewswire.com/news-release/2014/03/04/615319/10070984/en/Biodel-to-Present-at-the-26th-Annual-ROTH-Conference.html?f=22&fvtc=4&fvtv=14213Biodel to Present at the 26th Annual ROTH Conference2014-03-04T12:00:00Z<![CDATA[DANBURY, Conn., March 4, 2014 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) management will be presenting an overview of the Company's technologies, development programs, and outlook at the 26th Annual ROTH Conference being held at the Ritz-Carlton Laguna Niguel, CA from March 9-12, 2014. Interested parties can access a link to a live webcast of the presentation from the News & Events section of the Biodel website, ]]>https://www.globenewswire.com/news-release/2014/02/12/609816/10068237/en/Biodel-Announces-Plans-to-Advance-BIOD-531-Based-on-Positive-Clinical-Trial-Results.html?f=22&fvtc=4&fvtv=14213Biodel Announces Plans to Advance BIOD-531 Based on Positive Clinical Trial Results2014-02-12T21:30:43Z<![CDATA[Phase 1 Clinical Trial Data Demonstrate that Biodel's Concentrated Insulin BIOD-531 has a More Rapid Absorption and Onset of Action Versus Both Humulin® R U-500 and Humalog® Mix 75/25 and a Duration of Action Consistent with a Basal Insulin
Conference Call and Webcast Will be Held Today, February 12, 2014 at 5:00 pm EST]]>https://www.globenewswire.com/news-release/2014/02/06/608229/10067426/en/Biodel-Reports-First-Quarter-Fiscal-Year-2014-Financial-Results.html?f=22&fvtc=4&fvtv=14213Biodel Reports First Quarter Fiscal Year 2014 Financial Results2014-02-06T21:03:00Z<![CDATA[Conference Call and Audio Webcast Will be Held Today, February 6th, at 5:00 p.m. ET DANBURY, Conn., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the first fiscal quarter ended December 31, 2013.]]>https://www.globenewswire.com/news-release/2014/02/05/607743/10067181/en/Biodel-to-Report-First-Quarter-Fiscal-Year-2014-Financial-Results-on-February-6-2014.html?f=22&fvtc=4&fvtv=14213Biodel to Report First Quarter Fiscal Year 2014 Financial Results on February 6, 20142014-02-05T21:00:00Z<![CDATA[DANBURY, Conn., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) will issue its first quarter fiscal year 2014 financial results on February 6, 2014. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.]]>https://www.globenewswire.com/news-release/2014/02/04/607347/10066985/en/Biodel-to-Present-at-Upcoming-Conferences.html?f=22&fvtc=4&fvtv=14213Biodel to Present at Upcoming Conferences2014-02-04T21:15:00Z<![CDATA[DANBURY, Conn., Feb. 4, 2014 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) announced today that it will present at the following upcoming conferences:]]>https://www.globenewswire.com/news-release/2013/12/18/597943/10061833/en/Biodel-Reports-Fourth-Quarter-Fiscal-Year-2013-Financial-Results.html?f=22&fvtc=4&fvtv=14213Biodel Reports Fourth Quarter Fiscal Year 2013 Financial Results2013-12-18T21:30:00Z<![CDATA[Conference Call and Audio Webcast Will be Held Today, December 18th, at 5:00 p.m. ET DANBURY, Conn., Dec. 18, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the fourth fiscal quarter ended September 30, 2013.]]>